Report of Foreign Issuer (6-k)
08 May 2019 - 8:44PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 7, 2019
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk A/S purchases B shares worth DKK 2,235 million from Novo Holdings A/S under the 2019 share repurchase programme
Bagsværd, Denmark, 7 May 2019
–
Novo Nordisk A/S has today entered into an agreement to purchase 7,012,500 B shares of DKK 0.20 to a value of DKK 2,235 million
from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S’ 2019 share repurchase programme of up to a total of
DKK 15 billion to be executed during a 12- month period beginning 1 February 2019. The transaction price is DKK 318.71 per share
and has been calculated as the three-day volume weighted average market price from 3 May to 7 May 2019 in the open window following
the announcement of Novo Nordisk A/S’ quarterly financial results.
Prior to the sale of B shares, Novo Holdings
A/S’ ownership of Novo Nordisk A/S was 28.6% of the share capital and 76.3% of the votes. Following the transaction, Novo
Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 142,776,500 B shares of DKK 0.20, corresponding to 28.3% of the capital
and 76.2% of the votes in Novo Nordisk A/S.
The transaction is in line with the announcement
on 3 May 2019 that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S’ share capital around 28%.
With the transaction stated above, Novo
Nordisk A/S owns a total of 22,369,001 B shares of DKK 0.20, corresponding to 0.9% of the share capital, as treasury shares. The
total amount of A and B shares in the company is 2,400,000,000 of DKK 0.20 including treasury shares.
Page 2 of 2
About Novo Holdings A/S
Novo Holdings is a Danish private limited
liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk
A/S and Novozymes A/S, and is responsible for managing the Foundation’s assets.
In addition to being the major shareholder
in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant
ownership positions in well- established companies within life science and manages a broad portfolio of financial assets.
It is the vision of Novo Holdings
to be recognized as a world-leading life science investor with a focus on creating long-term value. Read more at www.novo-holdings.dk.
About Novo Nordisk A/S
Novo Nordisk is a global healthcare
company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities
that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered
in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For
more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Novo Holdings Communication
|
|
|
Christian Mostrup Scheel
|
+45 3067 4805
|
cims@novo.dk
|
|
|
|
Novo Nordisk Media:
|
|
|
Anne Margrethe Hauge
|
+45 4442 3450
|
amhg@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 240 9429
|
kiau@novonordisk.com
|
|
|
|
Novo Nordisk Investors
:
|
|
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
Kristoffer Due Berg (US)
|
+1 609 235 2989
|
krdb@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 31 / 2019
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 7, 2019
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024